Table 2 Outcome and immune... | American Society of Hematology

Table 2

Outcome and immune reconstitution after HSCT

	Patients
	1	2	3	4
Follow-up, mo	25	19	11	6
Donor chimerism, %	100	100	89	84.6
GVHD, acute/chronic	Grade 2 gut/extensive skin	0/0	0/0	0/0
Immunosuppression	FK506/photopheresis	No	No	Tapering prophylaxis
Lansky score	80	100	100	100
FOXP3⁺ cells
%*	52	77	72	33
Absolute no./mm³†	29	99	17	30
Absolute lymphocyte numbers, mm³¶;
CD4	446	2005	649	218
CD8	1757	792	193	44
B cells	124	1322	669	218
Lymphocyte proliferation to PHA, % normal control	26.5	100.2	78.6	35
Immunoglobulin level, mg/dL
IgG‡	681	502	769	1300
IgM§	149	42	48	79
IgA‖	54	96	121	18.3

	Patients
	1	2	3	4
Follow-up, mo	25	19	11	6
Donor chimerism, %	100	100	89	84.6
GVHD, acute/chronic	Grade 2 gut/extensive skin	0/0	0/0	0/0
Immunosuppression	FK506/photopheresis	No	No	Tapering prophylaxis
Lansky score	80	100	100	100
FOXP3⁺ cells
%*	52	77	72	33
Absolute no./mm³†	29	99	17	30
Absolute lymphocyte numbers, mm³¶;
CD4	446	2005	649	218
CD8	1757	792	193	44
B cells	124	1322	669	218
Lymphocyte proliferation to PHA, % normal control	26.5	100.2	78.6	35
Immunoglobulin level, mg/dL
IgG‡	681	502	769	1300
IgM§	149	42	48	79
IgA‖	54	96	121	18.3

Ranges: 76%-91%;

43-149/mm³;

608-1572 mg/dL;

52-352 mg/dL;

45-312 mg/dL.

Patients 1 and 2 were measured at 1 year; patient 3, at 9 months; and patient 4, at 6 months.